COEP Live signaler | Maksimer profitt med Getagraph.com

Live Chart Being Loaded With Signals

Commentary (3 mai 2024 @ 22:00):

Coeptis Therapeutics, Inc., a biopharmaceutical company, develops and commercializes generic and branded pharmaceutical products and cell therapy platforms for patients with cancer...

Stats
Dagens volum	315 806
Gjennomsnittsvolum	266 756
Markedsverdi	12.28M
EPS	$0 ( 2024-03-28 )
Neste inntjeningsdato	( $0 ) 2024-05-20
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.590
ATR14	$0.00400 (1.09%)

Insider Trading

Date	Person	Action	Amount	type
2024-01-10	Cogley Brian	Buy	5 000	Common Stock
2024-01-10	Cogley Brian	Sell	0	Common Stock
2024-01-12	Desilva Tara	Buy	1 800	Common Stock
2024-01-12	Desilva Tara	Buy	466	Common Stock
2024-01-05	Yerace Daniel Alexander	Buy	10 850	Common Stock

INSIDER POWER
67.24
Last 46 transactions
Buy: 10 280 996 \| Sell: 12 141 291

Volum Korrelasjon

Lang: 0.39 (neutral)

Kort: 0.62 (weak)

Signal:(47.147) Neutral

Coeptis Therapeutics, Korrelasjon

10 Mest positive korrelasjoner

10 Mest negative korrelasjoner

Visste du det?

Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).

Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.

Coeptis Therapeutics, Korrelasjon - Valuta/Råvare

-0.18
( neutral )

-0.09
( neutral )

0.00
( neutral )

-0.13
( neutral )

Coeptis Therapeutics, Økonomi

Annual	2023
Omsetning:	$0
Bruttogevinst:	$0 (0.00 %)
EPS:	$-0.830

FY	2023
Omsetning:	$0
Bruttogevinst:	$0 (0.00 %)
EPS:	$-0.830

FY	2022
Omsetning:	$0
Bruttogevinst:	$-1.00M (0.00 %)
EPS:	$-2.87

FY	2021
Omsetning:	$75 000.00
Bruttogevinst:	$75 000.00 (100.00 %)
EPS:	$-0.689

Financial Reports:

No articles found.

Coeptis Therapeutics,

Coeptis Therapeutics, Inc., a biopharmaceutical company, develops and commercializes generic and branded pharmaceutical products and cell therapy platforms for patients with cancer. Its product portfolio consists of CD38-GEAR-NK, a Vy-Gen drug product for the treatment of CD38-related cancers, including multiple myeloma, chronic lymphocytic leukemia, and acute myeloid leukemia; and CD38-Diagnostic, an in vitro screening tool to provide the ability to pre-determine which cancer patients are most likely to benefit from targeted anti-CD38 monoclonal antibodies therapies. The company has collaboration with Statera BioPharma to develop and commercialize STAT-201 for Crohn's disease; and Vici Health Sciences, LLC to co-develop and share ownership rights to CPT60621 for the treatment of Parkinson's Disease. Coeptis Therapeutics, Inc. was founded in 2017 and is headquartered in Wexford, Pennsylvania.